Nav: Home

US older women three times as likely to be treated for osteoporosis as men

February 14, 2019

US older women three times as likely to be treated for osteoporosis as men

Particular issue for men over the age of 80, most of whom meet treatment criteria

Older women in the US are three times as likely to be treated for osteoporosis as men of the same age, reveals research published online in the Journal of Investigative Medicine.

This is a particular issue for men aged 80+, most of whom meet the criteria for treatment, the findings show.

Some 10 million people in the US have osteoporosis, and there are 2 million associated fractures every year, at a cost of US$19 million. And these figures are expected to rise to 3 million fractures at a cost of $25 million by 2025 as the population ages.

Osteoporosis is a major health issue for men as their risks of death and illness after a hip fracture are higher than those of women, say the researchers.

But who would benefit most from testing and treatment remains a matter of debate, and it has been several years since treatment guidelines for men have been published.

The researchers compared the screening and treatment of osteoporosis in 13,704 men and women aged 70+ at one Veterans Affairs medical centre from January 2000 to August 2010.

Management included DXA scans, which measure bone mineral density; vitamin D level assessment; and treatment with vitamin D/calcium supplements and/or bisphosphonates.

They looked at two groups: 11,604 men and 463 women with age alone as a risk factor for hip fracture; and 1637 men at higher risk of osteoporosis, because of a previous fracture, steroid treatment, or hormone (androgen) deprivation therapy.

The researchers scored the risk of an osteoporotic hip fracture over the next 10 years, using a shortened version of a validated risk assessment tool (FRAX). This included factors such as ethnicity, age, weight and height, and previous fractures.

As expected, increasing age was associated with a heightened risk of fracture over the next decade for both men and women.

But around half (48%) of 75-79 year old men, with age alone as a risk factor, had a 10-year hip fracture risk of 3 per cent or higher, meaning they met the threshold criteria for treatment. This rose to 88 per cent of those aged 80 and above.

And among men at higher risk, the proportion of those with a 10 year hip fracture risk ranged from 69 to 95 per cent.

Management was less than optimal in both sexes. But men were significantly less likely than women to be tested and treated for osteoporosis, particularly those aged 80 above, even when they met the criteria for treatment.

When categorised by age alone, women were more than five times as likely to have a DXA scan (63% vs 12%) and around twice as likely to have their vitamin D levels assessed (39% vs 18%).

They were also more than three times as likely to be given calcium/vitamin D supplements (63% vs 20%) and significantly more likely to be treated with bisphosphonates (44% vs 5%).

Among men aged 80+, only between 10 and 13 per cent had had a bone density scan and fewer than one in 10 had been treated with bisphosphonates.

What's more, the testing and treatment of osteoporosis among men at higher hip fracture risk was "strikingly low," particularly those who had already had a hip fracture, note the researchers.

This is an observational study, and as such, can't establish cause, added to which veterans tend to have a higher rate of underlying illnesses, and so the findings might not be more widely applicable, caution the researchers.

It isn't clear why older men in the US don't get screened and treated for osteoporosis, they say. It might be that clinicians aren't aware of osteoporosis screening guidelines for men, or that busy doctors prioritise other illnesses in clinic, they suggest.

But their findings suggest that previous guidelines are "inadequate in effectively identifying older men who might benefit from evaluation for osteoporosis and fracture prevention treatment," they write.

"We believe that there is a need for developing strategies to improve the evaluation and management for all older men, particularly among elderly men with a very high risk of fracture," they conclude.
-end-


BMJ

Related Osteoporosis Articles:

New pharmaceutical target reverses osteoporosis in mice
Biomedical engineers at Duke University have discovered that an adenosine receptor called A2B can be pharmaceutically activated to reverse bone degradation caused by osteoporosis in mouse models of the disease.
A link between mitochondrial damage and osteoporosis
In healthy people, a tightly controlled process balances out the activity of osteoblasts, which build bone, and osteoclasts, which break it down.
Many stroke patients not screened for osteoporosis, despite known risks
Many stroke survivors have an increased risk of osteoporosis, falls or breaks when compared to healthy people.
Many postmenopausal women do not receive treatment for osteoporosis
The benefits of treating osteoporosis in postmenopausal women outweigh the perceived risks, according to a Clinical Practice Guideline issued today by the Endocrine Society.
A new 'atlas' of genetic influences on osteoporosis
A ground-breaking new study led by researchers from the Lady Davis Institute (LDI) at the Jewish General Hospital (JGH) has succeeded in compiling an atlas of genetic factors associated with estimated bone mineral density (BMD), one of the most clinically relevant factors in diagnosing osteoporosis.
New recommendations for the conduct of economic evaluations in osteoporosis
An expert working group has established recommendations for the design and conduct of economic evaluations in osteoporosis, as well as guidance for reporting these evaluations.
From receptor structure to new osteoporosis drugs
Researchers at the University of Zurich have determined the three-dimensional structure of a receptor that controls the release of calcium from bones.
How a Mediterranean diet could reduce osteoporosis
Eating a Mediterranean-type diet could reduce bone loss in people with osteoporosis -- according to new research from the University of East Anglia.
Osteoporosis drug may benefit heart health
The osteoporosis drug alendronate was linked with a reduced risk of cardiovascular death, heart attack, and stroke in a Journal of Bone and Mineral Research study of patients with hip fractures.
New treatment for osteoporosis provides better protection against fractures
A new treatment for osteoporosis provides major improvements in bone density and more effective protection against fractures than the current standard treatment.
More Osteoporosis News and Osteoporosis Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Rethinking Anger
Anger is universal and complex: it can be quiet, festering, justified, vengeful, and destructive. This hour, TED speakers explore the many sides of anger, why we need it, and who's allowed to feel it. Guests include psychologists Ryan Martin and Russell Kolts, writer Soraya Chemaly, former talk radio host Lisa Fritsch, and business professor Dan Moshavi.
Now Playing: Science for the People

#538 Nobels and Astrophysics
This week we start with this year's physics Nobel Prize awarded to Jim Peebles, Michel Mayor, and Didier Queloz and finish with a discussion of the Nobel Prizes as a way to award and highlight important science. Are they still relevant? When science breakthroughs are built on the backs of hundreds -- and sometimes thousands -- of people's hard work, how do you pick just three to highlight? Join host Rachelle Saunders and astrophysicist, author, and science communicator Ethan Siegel for their chat about astrophysics and Nobel Prizes.